フェノバルビタールの世界市場

フェノバルビタールの世界市場は2030年までに20億米ドルに到達

2024年に16億米ドルと推定されるフェノバルビタールの世界市場は、分析期間2024-2030年にCAGR 3.3％で成長し、2030年には20億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるてんかん適応症は、CAGR 2.7%を記録し、分析期間終了時には13億米ドルに達すると予測されます。新生児発作適応症分野の成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は推定4億3,800万米ドル、中国はCAGR6.1％で成長予測

米国のフェノバルビタール市場は、2024年に4億3,800万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.1％を引きずる形で、2030年までに3億8,480万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.5%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界のフェノバルビタール市場- 主要動向と促進要因のまとめ

新規抗てんかん薬の急増にもかかわらず、フェノバルビタールが臨床的に重要であり続ける理由とは？

20世紀初頭に発売された長時間作用型バルビツール酸系抗てんかん薬であるフェノバルビタールは、特に特定の患者集団や世界の医療環境において、抗てんかん治療の第一選択薬または補助薬としての治療的妥当性を維持し続けています。全般性強直間代発作および部分発作の治療におけるその有効性は、手ごろな価格と長い作用時間とともに、医療へのアクセスと費用抑制が優先される低・中所得国において好ましい選択肢となっています。世界保健機関（WHO）は、てんかん、特に資源に乏しい環境下にある小児集団のために、フェノバルビタールを必須薬に分類しています。

新世代の抗てんかん薬（AED）は副作用プロファイルが改善され、薬物相互作用も少なくなっていますが、フェノバルビタールは予測可能な薬物動態、投与の容易さ、世界的に入手可能であることから、特定の適応症においては依然としてゴールドスタンダードとなっています。フェノバルビタールは、特に新生児てんかんや小児てんかんにおいて、迅速な発作コントロールが必要とされる症例に使用されています。さらに、フェノバルビタールの鎮静剤や麻酔前投薬における有用性は、神経学にとどまらず、外科やクリティカルケアの場面でもその需要を拡大しています。

世界の医療政策、コスト制約、地域の治療ガイドラインはどのように需要を維持しているのか？

フェノバルビタールの強みの一つは、てんかんの負担が大きく、医療資源に制約のあるサハラ以南のアフリカ、東南アジア、ラテンアメリカの国家治療プロトコールに含まれていることです。多くの公衆衛生プログラムは、安価なてんかん治療を提供するために、政府調達やNGOの支援によるサプライチェーンに依存しており、フェノバルビタールの低い製造コスト、長い保存期間、経口・注射投与の容易さは、そのような枠組みにおける理想的な薬剤となっています。

しかし、長期使用者の依存性や認知機能の副作用に対する懸念から、市場の監視や規制も強まっています。ファーマコビジランス（医薬品安全性監視）システムが発達している国々では、レボフロキサンが規制薬物として指定されつつあり、高所得国の医師は、より安全性の高い新しいAEDを選択するため、レボフロキサンを段階的に廃止しています。とはいえ、レベチラセタム、ラモトリギン、カルバマゼピンへのアクセスが限られている地域では、フェノバルビタールは成人・小児ともに主要な治療選択肢であり続けています。

なぜ製剤革新と製造の現地化が戦略的に重要性を増しているのか？

必要不可欠な医薬品へのアクセスと現地生産能力に改めて注目が集まる中、輸入への依存を減らし、継続的な供給を確保するために、いくつかの国ではフェノバルビタール製剤の国内生産を支援しています。この動向は、患者のコンプライアンスを向上させ、介護者の負担を軽減する小児用風味シロップ剤、散剤、徐放性製剤などの剤形の革新につながっています。

一方、製造受託機関（CMO）や政府系製薬企業は、地政学的要因や規制措置によって中断されたサプライチェーンのギャップを埋めるために参入しています。品質保証とWHOの事前資格認定は、特にドナー資金や国連支援による医薬品調達システムに依存する輸出市場において、極めて重要になってきています。このような開発により、人道的、商業的な両面で、フェノバルビタールのサプライチェーンはより構造化され、強靭なものとなりつつあります。

世界のフェノバルビタール市場の継続的成長の原動力は？

フェノバルビタール市場の成長は、小児てんかん治療における持続的な使用、公衆衛生プロトコルへの組み入れ、資源に制約のある国々における必要不可欠な医薬品へのアクセスという経済的要請など、いくつかの要因によってもたらされています。主な成長要因は、ヘルスケアインフラが未発達または断片的な環境において、てんかん発作を管理する際の有効性と費用対効果が実証されていることです。

世界の疾病負担データによると、てんかん患者の80%以上が中低所得国に集中しており、フェノバルビタールは治療効果と経済性を両立させた数少ない抗てんかん薬の一つです。各国政府やNGOが、必要不可欠な医薬品のサプライチェーンやタスクシフティングモデルを通じて神経科医療を改善する取り組みを拡大する中、フェノバルビタールは重要な役割を果たし続けています。現在進行中の製剤革新、品質標準化、官民供給メカニズムの強化により、世界のフェノバルビタール市場は、地域的な偏りはあるもの、当分の間は安定した成長を維持するものと思われます。

セグメント

適応症（てんかん、新生児発作）;剤形（錠剤、カプセル剤、注射剤）;流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の32社）

• AdvaCare Pharma
• Alkaloida Chemical Company Zrt
• Asia Pioneer Pharmaceuticals
• Biotechnica DWC
• Cefa-Cilinas Biotics Pvt Ltd
• Chemische Fabrik Berg GmbH
• Fagron Group
• Harman Finochem Ltd
• HRV Global Life Sciences Pvt Ltd
• Incepta Pharmaceuticals Ltd
• JPN Pharma
• Manus Aktteva Biopharma LLP
• Moehs Iberica S.L.
• Nexus Pharmaceuticals LLC
• Opsonin Pharma Ltd
• Pfizer Inc.
• Piramal Healthcare Ltd
• Sanofi
• Siegfried AG
• Teva Pharmaceutical Industries Ltd

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Phenobarbital Market to Reach US$2.0 Billion by 2030

The global market for Phenobarbital estimated at US$1.6 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Epilepsy Indication, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Neonatal Seizures Indication segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$438.0 Million While China is Forecast to Grow at 6.1% CAGR

The Phenobarbital market in the U.S. is estimated at US$438.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$384.8 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Phenobarbital Market - Key Trends & Drivers Summarized

Why Does Phenobarbital Remain Clinically Relevant Despite the Surge in Newer Antiepileptic Drugs?

Phenobarbital, a long-acting barbiturate first introduced in the early 20th century, continues to maintain therapeutic relevance as a first-line or adjunctive antiepileptic treatment-especially in specific patient populations and global health settings. Its effectiveness in managing generalized tonic-clonic and partial seizures, along with its affordability and long duration of action, make it a preferred choice in low- and middle-income countries where healthcare access and cost containment are priorities. The World Health Organization (WHO) has classified phenobarbital as an essential medicine for epilepsy, particularly for pediatric populations in resource-limited settings.

Despite newer-generation antiepileptic drugs (AEDs) offering improved side effect profiles and fewer drug interactions, phenobarbital remains a gold standard in certain indications due to its predictable pharmacokinetics, ease of administration, and global availability. It is especially utilized in neonatal and pediatric epilepsy cases where rapid seizure control is necessary. Moreover, phenobarbital’s utility in sedative and pre-anesthesia applications extends its demand beyond neurology and into surgical and critical care settings.

How Are Global Health Policies, Cost Constraints, and Regional Treatment Guidelines Sustaining Demand?

One of the core strengths of phenobarbital lies in its inclusion in national treatment protocols across sub-Saharan Africa, Southeast Asia, and Latin America, where epilepsy burden is high and healthcare resources are constrained. Many public health programs rely on government procurement or NGO-backed supply chains to deliver affordable epilepsy care, and phenobarbital’s low manufacturing cost, long shelf life, and ease of oral and injectable administration make it an ideal agent in such frameworks.

However, the market is also seeing increasing scrutiny and regulation due to concerns over dependence potential and cognitive side effects in long-term users. Countries with advanced pharmacovigilance systems are placing phenobarbital under controlled substance schedules, and physicians in high-income nations are progressively phasing it out in favor of newer AEDs with better safety profiles. Nevertheless, in regions where access to levetiracetam, lamotrigine, or carbamazepine is limited, phenobarbital remains the primary therapeutic option for both adults and children.

Why Are Formulation Innovation and Manufacturing Localization Gaining Strategic Importance?

With a renewed focus on essential medicines access and local production capabilities, several countries are supporting domestic manufacturing of phenobarbital formulations to reduce dependency on imports and secure continuous supply. This trend is leading to innovations in dosage forms, such as flavored pediatric syrups, dispersible tablets, and extended-release formulations that improve patient compliance and reduce caregiver burden.

Meanwhile, contract manufacturing organizations (CMOs) and government-owned pharma entities are stepping in to fill gaps in supply chains disrupted by geopolitical factors or regulatory actions. Quality assurance and WHO prequalification are becoming crucial, especially in export markets that rely on donor-funded or UN-supported drug procurement systems. These developments are driving a more structured and resilient supply chain for phenobarbital in both humanitarian and commercial contexts.

What’s Fueling the Continued Growth of the Phenobarbital Market Globally?

The growth in the phenobarbital market is driven by several factors including sustained use in pediatric epilepsy care, its inclusion in public health protocols, and the economic imperatives of essential drug access in resource-constrained countries. A key growth driver is its proven efficacy and cost-effectiveness in managing seizure disorders in settings where healthcare infrastructure remains underdeveloped or fragmented.

Global disease burden data indicate that over 80% of epilepsy cases are found in low- and middle-income countries, and phenobarbital remains one of the few antiepileptics that combines therapeutic potency with economic feasibility. As governments and NGOs scale up efforts to improve neurology care through essential drug supply chains and task-shifting models, phenobarbital continues to play a critical role. With ongoing formulation innovations, quality standardization, and reinforced public-private supply mechanisms, the global phenobarbital market is poised to maintain steady, if regionally skewed, growth for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Phenobarbital market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Epilepsy, Neonatal Seizures); Form (Tablets, Capsules, Injectables); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AdvaCare Pharma
• Alkaloida Chemical Company Zrt
• Asia Pioneer Pharmaceuticals
• Biotechnica DWC
• Cefa-Cilinas Biotics Pvt Ltd
• Chemische Fabrik Berg GmbH
• Fagron Group
• Harman Finochem Ltd
• HRV Global Life Sciences Pvt Ltd
• Incepta Pharmaceuticals Ltd
• JPN Pharma
• Manus Aktteva Biopharma LLP
• Moehs Iberica S.L.
• Nexus Pharmaceuticals LLC
• Opsonin Pharma Ltd
• Pfizer Inc.
• Piramal Healthcare Ltd
• Sanofi
• Siegfried AG
• Teva Pharmaceutical Industries Ltd

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Phenobarbital - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Burden of Epilepsy and Seizure Disorders Drives Sustained Demand for Phenobarbital Therapies
  • Expansion of Access to Essential Medicines in LMICs Throws the Spotlight on Phenobarbital as a First-Line AED
  • OEM Innovation in Pediatric and Oral Liquid Formulations Enhances Dosing Accuracy and Adherence
  • Growth in Animal Health and Veterinary Neurology Spurs Demand in Companion Animal Seizure Treatments
  • OEM Development of Sustained-Release Formulations Supports Management of Chronic Epileptic Conditions
  • Rising Application in Sedation and Pre-Anesthetic Use Cases Propels Broader Clinical Demand
  • OEM Collaboration With WHO and National Health Ministries Strengthens Public Sector Procurement of Phenobarbital
  • Increasing Concerns Over Drug Shortages and Supply Chain Stability Drives Local Manufacturing Initiatives
  • OEM Advances in Pharmacovigilance Platforms Improve Safety Monitoring in High-Risk and Long-Term Users
  • Growth in Off-Label Use for Status Epilepticus and Alcohol Withdrawal Syndromes Expands Therapeutic Applications
  • OEM Emphasis on Biosafety and Compliance With Controlled Substance Regulations Enhances Production Oversight
  • Rising Demand for Low-Cost, High-Efficacy Anticonvulsants in Rural Health Networks Supports Government Funding
  • OEM Focus on Fixed-Dose Combinations With Other AEDs Enhances Polytherapy Efficiency
  • Expansion of International Essential Drug Lists Drives Long-Term Market Inclusion for Phenobarbital
  • OEM Participation in Global Pediatric Neurology Trials Enhances Evidence-Based Adoption
  • Growth in Neurological Disease Awareness Campaigns Drives Diagnosis and Treatment Initiation
  • OEM Investment in Shelf-Stable, Low-Cost Formulations Supports Humanitarian and Relief Agency Distribution
  • Rising Scrutiny on Barbiturate Abuse and Dependence Profiles Spurs Educational and Risk Management Initiatives
  • OEM Development of Generic and Branded Variants Strengthens Market Competition in Key Regions
  • Global Harmonization of Pharmacopoeial Standards Enhances Consistency in Manufacturing and Labeling
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Phenobarbital Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Phenobarbital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Phenobarbital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Phenobarbital by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Neonatal Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Neonatal Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Neonatal Seizures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Phenobarbital by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Phenobarbital by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Phenobarbital by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Phenobarbital by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Phenobarbital by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Phenobarbital by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Phenobarbital by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Phenobarbital by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Phenobarbital by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Phenobarbital by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Phenobarbital by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Phenobarbital by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Phenobarbital Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Phenobarbital by Indication - Epilepsy and Neonatal Seizures - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Phenobarbital by Indication - Epilepsy and Neonatal Seizures Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Phenobarbital by Indication - Percentage Breakdown of Value Sales for Epilepsy and Neonatal Seizures for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Phenobarbital by Form - Tablets, Capsules and Injectables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Phenobarbital by Form - Tablets, Capsules and Injectables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Phenobarbital by Form - Percentage Breakdown of Value Sales for Tablets, Capsules and Injectables for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Phenobarbital by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Phenobarbital by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION